Contact

Press release from PAXMAN AB’s 2026 Annual General Meeting

PAXMAN´s AGM was held today, 22 May 2026, in Karlshamn. Almost 36,4 % of all issued shares were represented at the meeting. After the formal AGM, CEO Richard Paxman gave a digital company presentation and responded to questions from the attending shareholders.

In accordance with the Nomination Committee’s proposal, the AGM resolved that the Board of Directors shall consist of seven ordinary members with no deputy members until the Annual General Meeting 2027. The Board was largely re-elected in its entirety. Björn Littorin had declined re-election. The AGM resolved to elect Mats Hyttinge as a new Board member.

Accordingly, the Board of Directors will continue to consist of Per-Anders Johansson (Chairman of the Board), Robert Kelly, Glenn Paxman, Richard Paxman, Maria Bech and Karen Giddings Clakely, together with newly elected Board member Mats Hyttinge.
Also in accordance with the Nomination Committee’s proposal, the accountancy firm Ernst & Young AB was re-elected as auditor. Ernst & Young AB has announced that Henrik Rosengren will continue as auditor-in-charge.

The Meeting further resolved that the total fees payable to the Board, excluding travel expenses, will be 550,000 SEK per annum, of which 150,000 SEK payable to the Chairman of the Board and 100,000 SEK to each of the Board Members elected by the AGM who are not employed by the company.

The AGM also resolved, in accordance with the Board of Directors’ proposal, to adopt an incentive programme for employees in the subsidiaries Paxman US, Inc. and Dignitana, Inc. (“Program US TO 2026”).

Finally, the AGM resolved, in accordance with the Board of Directors’ proposal, to amend the Articles of Association in order to enable additional share issuances. The amendment entails adjustments to the limits regarding the number of shares and the share capital.

All resolutions made by the AGM were unanimous.

Press release from PAXMAN AB’s 2026 Annual General Meeting Press release from PAXMAN AB’s 2026 Annual General Meeting
What we do
Paxman are world leaders in chemotherapy side effect management on an ambitious journey to change the face of cancer through cryotherapy-based treatments. The Paxman mission is to democratise access to scalp cooling globally.
Learn more →
Financial Information
Read the latest Paxman financial reports. In these comprehensive documents, you will find a detailed overview of our financial performance, key milestones, and a strategic outlook for the future. Reports are published quarterly and annually.
Read reports  →
Investing in Paxman
Paxman has treated 100,000+ patients and installed 5,000+ systems in more than 65 countries worldwide. We are helping to manage the trauma of chemotherapy hair loss. By investing in Paxman, you're not just supporting a company; you're joining us in changing the face of cancer.
Visit the Investor Centre →
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram